Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.75 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23033613 | 0.94 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL5226075 | 0.86 | SIGMAR1 (0.61) | SIGMAR1MPOKCNH2 | |
| SCHEMBL4254894 | 0.86 | SIGMAR1 (1.00) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL3681105 | 0.85 | SIGMAR1 (0.79) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL8935187 | 0.85 | SIGMAR1 (0.79) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL2538905 | 0.84 | SIGMAR1 (0.95) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL6895156 | 0.83 | SIGMAR1 (0.76) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL7298415 | 0.83 | SIGMAR1 (0.76) | SIGMAR1 | |
| SCHEMBL8092310 | 0.82 | SIGMAR1 (0.95) | SIGMAR1 | |
| SCHEMBL20169118 | 0.82 | SIGMAR1 (0.82) | SIGMAR1DRD2DRD4DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005087217-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |